Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma

Pigment Cell and Melanoma Research

Volumn 26, Issue 6, 2013, Pages 886-899

  Madhunapantula, Subbarao V ^a,b   Sharma, Arati ^a,b   Gowda, Raghavendra ^a   Robertson, Gavin P ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

GSK3 ; GSK3 ; Kinase targets; Malignant melanoma; SiRNA library screening

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GROWTH REGULATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR VOLUME;

GSK3 Α; GSK3 Β; KINASE TARGETS; MALIGNANT MELANOMA; SIRNA LIBRARY SCREENING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; G0 PHASE; G1 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MELANOCYTES; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RNA, SMALL INTERFERING; SKIN NEOPLASMS; THIAZOLES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886259126     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12156     Document Type: Article

References (71)

1. Ali, A., Hoeflich, K.P., and Woodgett, J.R. (2001). Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101, 2527-2540.
2. Barretina, J., Caponigro, G., Stransky, N. et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607.
3. Bellei, B., Flori, E., Izzo, E., Maresca, V., and Picardo, M. (2008). GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell. Signal. 20, 1750-1761.
4. Bhat, R., Xue, Y., Berg, S. et al. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945.
5. Birmingham, A., Selfors, L.M., Forster, T. et al. (2009). Statistical methods for analysis of high-throughput RNA interference screens. Nat. Methods 6, 569-575.
6. Bonet, C., Giuliano, S., Ohanna, M., Bille, K., Allegra, M., Lacour, J.P., Bahadoran, P., Rocchi, S., Ballotti, R., and Bertolotto, C. (2012). Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J. Biol. Chem. 287, 29887-29898.
7. Chang, T.T., and Chou, T.C. (2000). Rational approach to the clinical protocol design for drug combinations: a review. Acta. Paediatr. Taiwan 41, 294-302.
8. Cheung, M., Sharma, A., Madhunapantula, S.V., and Robertson, G.P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 3429-3439.
9. Darrington, R.S., Campa, V.M., Walker, M.M., Bengoa-Vergniory, N., Gorrono-Etxebarria, I., Uysal-Onganer, P., Kawano, Y., Waxman, J., and Kypta, R.M. (2012). Distinct expression and activity of GSK-3alpha and GSK-3beta in prostate cancer. Int. J Caner 131, E872-883.
10. Dummer, R., and Flaherty, K.T. (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150-154.
11. Eberle, J., Spangler, B., Becker, J.C. et al. (2010). Multicentre study on standardisation of melanoma cell culture-an initiative of the German Melanoma Research Network. Pigment Cell Melanoma Res. 23, 296-298.
12. Emery, C.M., Vijayendran, K.G., Zipser, M.C. et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416.
13. Falschlehner, C., Steinbrink, S., Erdmann, G., and Boutros, M. (2010). High-throughput RNAi screening to dissect cellular pathways: a how-to guide. Biotechnol. J. 5, 368-376.
14. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
15. Force, T., and Woodgett, J.R. (2009). Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J. Biol. Chem. 284, 9643-9647.
16. Forde, J.E., and Dale, T.C. (2007). Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 64, 1930-1944.
17. Ganesan, A.K., Ho, H., Bodemann, B. et al. (2008). Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. PLoS Genet. 4, e1000298.
18. Garcea, G., Manson, M.M., Neal, C.P., Pattenden, C.J., Sutton, C.D., Dennison, A.R., and Berry, D.P. (2007). Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? Curr. Cancer Drug Targets 7, 209-215.
19. Gazdar, A.F., Gao, B., and Minna, J.D. (2010). Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer 68, 309-318.
20. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
21. Greger, J.G., Eastman, S.D., Zhang, V., Bleam, M.R., Hughes, A.M., Smitheman, K.N., Dickerson, S.H., Laquerre, S.G., Liu, L., and Gilmer, T.M. (2012). Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920.
22. Gremel, G., Rafferty, M., Lau, T.Y., and Gallagher, W.M. (2009). Identification and functional validation of therapeutic targets for malignant melanoma. Crit. Rev. Oncol. Hematol. 72, 194-214.
23. Huang, W., Chang, H.Y., Fei, T., Wu, H., and Chen, Y.G. (2007). GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26, 2471-2482.
24. Huh, S.J., Chen, Y.L., Friedman, S.L., Liao, J., Huang, H.J., Cavenee, W.K., and Robertson, G.P. (2010). KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J. Natl Cancer Inst. 102, 1131-1147.
25. Inamdar, G.S., Madhunapantula, S.V., and Robertson, G.P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol. 80, 624-637.
26. Iorns, E., Lord, C.J., and Ashworth, A. (2009). Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 417, 361-370.
27. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
28. John, J.K., Paraiso, K.H., Rebecca, V.W. et al. (2012). GSK3beta inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J. Invest. Dermatol. 132, 2818-2827.
29. Kannoji, A., Phukan, S., Sudher Babu, V., and Balaji, V.N. (2008). GSK3beta: a master switch and a promising target. Expert Opin. Ther. Targets 12, 1443-1455.
30. Katipamula, R., and Markovic, S.N. (2008). Emerging therapies for melanoma. Expert Rev. Anticancer Ther. 8, 553-560.
31. Kotliarova, S., Pastorino, S., Kovell, L.C. et al. (2008). Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 68, 6643-6651.
32. Krishan, A. (1975). Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66, 188-193.
33. Linos, E., Swetter, S.M., Cockburn, M.G., Colditz, G.A., and Clarke, C.A. (2009). Increasing burden of melanoma in the United States. J. Invest. Dermatol. 129, 1666-1674.
34. Liu, C., Zhao, G., Liu, J., Ma, N., Chivukula, P., Perelman, L., Okada, K., Chen, Z., Gough, D., and Yu, L. (2009). Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 140, 277-283.
35. Luo, J. (2009). Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194-200.
36. Madhunapantula, S.V., and Robertson, G.P. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 68, 5-8.
37. Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419.
38. Madhunapantula, S.V., Sharma, A., and Robertson, G.P. (2007). PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67, 3626-3636.
39. Madhunapantula, S.V., Desai, D., Sharma, A., Huh, S., Amin, S., and Robertson, G.P. (2008). PBIse, a novel selenium containing drug for the treatment of malignant melanoma. Mol. Cancer Ther. 7, 1297-1308.
40. Madhunapantula, S.V., Hengst, J., Gowda, R., Fox, T.E., Yun, J.K., and Robertson, G.P. (2012). Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 25, 259-274.
41. Mamaghani, S., Patel, S., and Hedley, D.W. (2009). Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 9, 132.
42. Micklem, D.R., and Lorens, J.B. (2007). RNAi screening for therapeutic targets in human malignancies. Curr. Pharm. Biotechnol. 8, 337-343.
43. Naito, S., Bilim, V., Yuuki, K., Ugolkov, A., Motoyama, T., Nagaoka, A., Kato, T., and Tomita, Y. (2010). Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin. Cancer Res. 16, 5124-5132.
44. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
45. Nguyen, N., Sharma, A., Sharma, A.K., Desai, D., Huh, S.J., Amin, S., Meyers, C., and Robertson, G.P. (2011). Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev. Res. (Phila.) 4, 248-258.
46. Ougolkov, A.V., and Billadeau, D.D. (2006). Targeting GSK-3: a promising approach for cancer therapy? Future Oncol. 2, 91-100.
47. Pacheco, I., Buzea, C., and Tron, V. (2011). Towards new therapeutic approaches for malignant melanoma. Expert Rev. Mol. Med. 13, e33.
48. Panka, D.J., Cho, D.C., Atkins, M.B., and Mier, J.W. (2008). GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J. Biol. Chem. 283, 726-732.
49. Rayasam, G.V., Tulasi, V.K., Sodhi, R., Davis, J.A., and Ray, A. (2009). Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 156, 885-898.
50. Robertson, G.P., Furnari, F.B., Miele, M.E., Glendening, M.J., Welch, D.R., Fountain, J.W., Lugo, T.G., Huang, H.J., and Cavenee, W.K. (1998). In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl Acad. Sci. USA 95, 9418-9423.
51. Rovedo, M.A., Krett, N.L., and Rosen, S.T. (2011). Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J. Invest. Dermatol. 131, 1442-1449.
52. Shakoori, A., Mai, W., Miyashita, K., Yasumoto, K., Takahashi, Y., Ooi, A., Kawakami, K., and Minamoto, T. (2007). Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 98, 1388-1393.
53. Shao, Y., and Aplin, A.E. (2010). Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681.
54. Sharma, A., Trivedi, N.R., Zimmerman, M.A., Tuveson, D.A., Smith, C.D., and Robertson, G.P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412-2421.
55. Sharma, A., Sharma, A.K., Madhunapantula, S.V., Desai, D., Huh, S.J., Mosca, P., Amin, S., and Robertson, G.P. (2009), Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin. Cancer Res. 15, 1674-1685.
56. Sharma, A.K., Kline, C.L., Berg, A., Amin, S., and Irby, R.B. (2011). The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin. Cancer Res. 17, 4474-4483.
57. Sharma, A., Madhunapantula, S.V., Gowda, R., Berg, A., Neves, R.I., and Robertson, G.P. (2013). Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am. J. Pathol. 182, 1151-1162.
58. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
59. Simard, E.P., Ward, E.M., Siegel, R., and Jemal, A. (2012). Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J. Clin. 62, 118-128.
60. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136-1144.
61. Smalley, K.S., Contractor, R., Haass, N.K. et al. (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67, 209-217.
62. Solit, D.B., and Rosen, N. (2011). Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774.
63. Stahl, J.M., Cheung, M., Sharma, A., Trivedi, N.R., Shanmugam, S., and Robertson, G.P. (2003). Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881-2890.
64. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
65. Tran, M.A., Gowda, R., Sharma, A., Park, E.J., Adair, J., Kester, M., Smith, N.B., and Robertson, G.P. (2008). Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 68, 7638-7649.
66. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
67. Wang, Z., Smith, K.S., Murphy, M., Piloto, O., Somervaille, T.C., and Cleary, M.L. (2008). Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455, 1205-1209.
68. Werzowa, J., Koehrer, S., Strommer, S., Cejka, D., Fuereder, T., Zebedin, E., and Wacheck, V. (2011). Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J. Invest. Dermatol. 131, 495-503.
69. Wilson, W. 3rd, and Baldwin, A.S. (2008). Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res. 68, 8156-8163.
70. Zhang, H., Hoang, T., Saeed, B., and Ng, S.C. (1996). Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Prostate 29, 69-76.
71. Zhang, X.D., Gillespie, S.K., and Hersey, P. (2004). Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol. Cancer Ther. 3, 187-197.